Literature DB >> 868907

Comparison of amikacin and gentamicin in the treatment of urinary tract infections.

D N Gilbert, N Eubanks, J Jackson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 868907     DOI: 10.1016/0002-9343(77)90662-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  6 in total

1.  [Clinical efficacy, nephrotoxicity and ototoxicity of amikacin].

Authors:  P Federspil; K Schindler; C Weich; E Tiesler; W Schätzle; M Ziegler
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  Comparison of moxalactam and gentamicin in the treatment of complicated urinary tract infections.

Authors:  R G Penn; L C Preheim; C C Sanders; D K Giger
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

3.  Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an In Vitro Model of Intracellular Infection.

Authors:  Françoise Van Bambeke; Marta Putrinš; Ivana Kerkez; Paul M Tulkens; Tanel Tenson
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

4.  Glomerular filtration rate determination by creatinine and cystatin-C in patients with acute pyelonephritis.

Authors:  Hadi Sorkhi; Raheleh Behzadi; Neda Joghtaei; Mohammad Poornasrollah; Ali Bijani
Journal:  Caspian J Intern Med       Date:  2018

5.  The predictive potential of different molecular markers linked to amikacin susceptibility phenotypes in Pseudomonas aeruginosa.

Authors:  Wedad M Nageeb; Helal F Hetta
Journal:  PLoS One       Date:  2022-04-25       Impact factor: 3.752

6.  Utilising cumulative antibiogram data to enhance antibiotic stewardship capacity in the Cape Coast Teaching Hospital, Ghana.

Authors:  Mavis Puopelle Dakorah; Elizabeth Agyare; Joseph Elikem Efui Acolatse; George Akafity; John Stelling; Victoria J Chalker; Owen B Spiller; Nana Benyin Aidoo; Frederick Kumi-Ansah; Daniel Azumah; Stephen Laryea; Robert Incoom; Eric Kofi Ngyedu
Journal:  Antimicrob Resist Infect Control       Date:  2022-10-03       Impact factor: 6.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.